MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew Fell, John A. Morrow, Duane E. DeMong et al.|Journal of Pharmacology and Experimental Therapeutics|2015Cited by 336